Abelacimab

Abelacimab
Monoclonal antibody
TypeWhole antibody
TargetFactor XI and its active form Factor XIa
Clinical data
Other namesMAA868
AHFS/Drugs.comMonograph
License data
Routes of
administration		Intravenous
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
KEGG

Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of coagulation,[1] under development by Anthos Therapeutics.

Mechanism of action

It is anti-factor XI antibody.[1][2]

See also

References

  1. ^ a b Verhamme P, Yi BA, Segers A, Salter J, Bloomfield D, Büller HR, et al. (August 2021). "Abelacimab for Prevention of Venous Thromboembolism". The New England Journal of Medicine. 385 (7): 609–617. doi:10.1056/NEJMoa2105872. PMID 34297496. S2CID 236198598.
  2. ^ "Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC (Direct Oral Anticoagulant)". Business Wire. 18 September 2023.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.